Anita Kumar, MD
Although biological criteria carry prognostic value in mantle cell lymphoma (MCL), initial observation based solely on clinical criteria was found to be an effective management strategy that did not compromise patient outcomes, according to a retrospective analysis published in Haematologica
Patients who underwent a period of initial observation had superior overall survival (OS) compared with patients who were immediately treated. At a median follow-up of 44 months, the median rates of OS were 11.4 years and 9.4 years among patients in the observation and treatment arms, respectively (P
= .043). However, there was no difference in outcome between arms from the start of treatment to death (P
= .99). This suggests that the extended survival among patients who underwent initial observation is not a result of greater treatment sensitivity, but due to their more favorable clinical presentation and disease biology, noted first author Anita Kumar, MD, and investigators, in the publication.
“Our study confirms that initial expectant monitoring is an appropriate management strategy for MCL patients and is not associated with inferior outcomes,” wrote Kumar, a medical oncologist at Memorial Sloan Kettering Cancer Center, and colleagues.
... to read the full story